Immunotherapies are among the most promising approaches to treating cancer. They work on the basis of systematically strengthening the body’s own immune system to eliminate cancer cells. So far they have achieved impressive results, for example in the treatment of melanoma or cancer of the lungs and kidneys.
The newly established spin-off Anaveon also has this high-potential field in its sights: “We’ve developed a special antibody that we’ll now be testing in clinical trials for the treatment of various types of cancer,” explains Onur Boyman, co-founder of the company and director of the Department of Immunology at the University Hospital Zurich. The spin-off has been launched with the help of investment from UZH Life Sciences Fund and the BaseLaunch.
Please click here for the full article.
See also about Anaveon
BaseLaunch up to a solid Phase II start
Onur Boyman and Andreas Katopodis featured in our BaseLaunch video
